Department of Urology, San Raffaele Turro Hospital, Milan, Italy.
Urology. 2013 Jun;81(6):1291-6. doi: 10.1016/j.urology.2012.11.078. Epub 2013 Mar 19.
To assess the complication rates and quality of life in patients eligible for focal therapy who underwent template-assisted transperineal prostate biopsy (TTPB).
Eighty-seven patients with low-risk prostate cancer (clinical stage T1c-T2a, prostate-specific antigen level ≤10 ng/mL, biopsy Gleason score ≤6), who were candidates for focal therapy, underwent TTPB. The study details are available from http://clinicaltrials.gov (NCT00928603). The primary outcomes were the complication rates, according to the Clavien-Dindo classification, and changes in the quality of life, evaluated using the International Prostate Symptom Score, International Index of Erectile Function, and Functional Assessment of Cancer Therapy-Prostate questionnaires, before and 1 month after TTPB.
The median patient age was 63.9 years (range 46-78), with a median Charlson comorbidity index of 2.2 (range 0-4). No statistically significant differences were observed when comparing the general and/or specific domains of the International Prostate Symptom Score, International Index of Erectile Function, and Functional Assessment of Cancer Therapy-Prostate results before and 1 month after TTPB (P >.05 for all). Using the Clavien-Dindo classification, we observed 37 cases of grade 1 complications, including 5 (6.1%) cases of macrohematuria, 13 (16%) of hemospermia, 11 (13.5%) of perineal hematoma, 3 (3.7%) of perineal hematoma and hemospermia, and 5 (6.1%) of macrohematuria and hemospermia. Three patients (3.7%) developed a grade II complication (ie, acute urinary retention). Prostate cancer was detected in 54 patients (62.1%). Of 57 patients, 16 (29.6%) were upgraded from Gleason score 3+3/atypical small acinar proliferation to Gleason score 7. Of the 54 patients with positive TTPB findings, 18 (25.3%) showed an anatomic correspondence between the results of previous biopsies and TTPB.
TTPB did not appear to have a significant effect on the quality of life of candidates for focal therapy, and the Clavien-Dindo complication rate was negligible.
评估接受模板辅助经会阴前列腺活检(TTPB)的适合局部治疗患者的并发症发生率和生活质量。
87 例低危前列腺癌(临床分期 T1c-T2a,前列腺特异性抗原水平≤10ng/ml,活检 Gleason 评分≤6)患者,为局部治疗候选者,行 TTPB。研究详情可在 http://clinicaltrials.gov(NCT00928603)获取。主要结局指标为根据 Clavien-Dindo 分类的并发症发生率和 TTPB 前后使用国际前列腺症状评分、国际勃起功能指数和癌症治疗功能评估-前列腺问卷评估的生活质量变化。
中位患者年龄为 63.9 岁(范围 46-78),中位 Charlson 合并症指数为 2.2(范围 0-4)。TTPB 前后比较,国际前列腺症状评分、国际勃起功能指数和癌症治疗功能评估-前列腺的一般和/或特定领域的结果均无统计学差异(所有 P>.05)。根据 Clavien-Dindo 分类,我们观察到 37 例 1 级并发症,包括 5 例(6.1%)镜下血尿、13 例(16%)血精、11 例(13.5%)会阴血肿、3 例(3.7%)会阴血肿和血精、5 例(6.1%)镜下血尿和血精。3 例(3.7%)发生 2 级并发症(即急性尿潴留)。54 例患者(62.1%)检测到前列腺癌。57 例患者中,16 例(29.6%)从 Gleason 评分 3+3/非典型小腺泡增生升级为 Gleason 评分 7。54 例 TTPB 阳性结果患者中,18 例(25.3%)TTPB 结果与之前活检结果在解剖学上具有对应性。
TTPB 似乎对局部治疗候选者的生活质量没有显著影响,Clavien-Dindo 并发症发生率可以忽略不计。